132 related articles for article (PubMed ID: 19203542)
1. Pharmacokinetic study of S-1.
Mende B; Krauss J; Thyssen D; Kredtke S; Scheulen ME; Strumberg D; Hanauske A; Makris L; Scigalla P; Urrea PD; Hilger RA
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):65-7. PubMed ID: 19203542
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
[TBL] [Abstract][Full Text] [Related]
4. New anti-cancer agent S-1: metabolism based drug combination.
Yamamoto Y; Matsushima E; Nagayama S; Fukushima M; Kawaguchi Y
Pharmazie; 2000 Mar; 55(3):244. PubMed ID: 10756550
[No Abstract] [Full Text] [Related]
5. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium.
Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y
Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Liu HY; Ding L; Yu Y; Chu Y; Zhu H
Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
[TBL] [Abstract][Full Text] [Related]
8. An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Takezako Y; Morizane C
Oncology; 2005; 68(2-3):171-8. PubMed ID: 16006754
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
Hirata K; Horikoshi N; Aiba K; Okazaki M; Denno R; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Shirasaka T
Clin Cancer Res; 1999 Aug; 5(8):2000-5. PubMed ID: 10473078
[TBL] [Abstract][Full Text] [Related]
10. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
[TBL] [Abstract][Full Text] [Related]
11. Fluorouracil (5FU) pharmacokinetics in 5FU prodrug formulations with a dihydropyrimidine dehydrogenase inhibitor.
Peters GJ; van Groeningen CJ; Giaccone G
J Clin Oncol; 2001 Nov; 19(22):4267-9. PubMed ID: 11709571
[No Abstract] [Full Text] [Related]
12. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
13. S-1-induced, prolonged complete regression of lung metastasis from gastric cancer refractory to 5'-DFUR: a case report with pharmacokinetic study.
Ueda Y; Yamagishi H; Yamashita T; Itoh N; Itoi H; Shirasaka T; Ajani JA
Jpn J Clin Oncol; 2004 May; 34(5):282-6. PubMed ID: 15231865
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer.
Oshima T; Yamada R; Hatori S; Kunisaki C; Imada T
Oncol Rep; 2006 Aug; 16(2):361-6. PubMed ID: 16820916
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors.
van Groeningen CJ; Peters GJ; Schornagel JH; Gall H; Noordhuis P; de Vries MJ; Turner SL; Swart MS; Pinedo HM; Hanauske AR; Giaccone G
J Clin Oncol; 2000 Jul; 18(14):2772-9. PubMed ID: 10894878
[TBL] [Abstract][Full Text] [Related]
17. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
18. Oral fluoropyrimidines in colorectal cancer.
Van Cutsem E; Peeters M
Semin Oncol; 2000 Oct; 27(5 Suppl 10):91-5. PubMed ID: 11049039
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
20. Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer.
Lim HS; Ryu KW; Lee JH; Kim YW; Ju Choi I; Kim MJ; Park YI; Hwang A; Park SR
J Clin Pharmacol; 2015 Aug; 55(8):926-35. PubMed ID: 25810324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
